Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Antibody Discovery
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Fc Region and Effector Functions
3.6.1. Types of Fc Receptors
3.6.2. Engineering of the Fc Region
3.6.2.1. Glycoengineering
3.6.2.2. Protein Engineering
3.6.2.3. Isotype Chimerism

3.7. Future of Engineered Antibodies

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Fc Protein Engineered and Glycoengineered Antibodies: Pipeline Review
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Disease Indication
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Gene
4.2.5. Analysis by Type of Antibody
4.2.6. Analysis by Type of Fc Engineering
4.2.7. Analysis by Impact of Fc Engineering
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Type of Therapy
4.2.10. Popular Fc Engineering Technologies: Analysis by Number of Development Programs
4.3. Fc Protein Engineered and Glycoengineered Antibodies: List of Developers
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size
4.3.3 Analysis by Location of Headquarters

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AbbVie
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Drug Portfolio
5.2.3.1 Drug Profile: Skyrizi
5.2.4 Recent Developments and Future Outlook
5.3. Alexion Pharmaceuticals
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Drug Portfolio
5.3.3.1. Drug Profile: Soliris
5.3.3.2. Drug Profile: Ultomiris
5.3.4. Recent Developments and Future Outlook
5.4. AstraZeneca
5.4.1. Company Overview
5.4.2. Financial Performance
5.4.3. Drug Portfolio
5.4.3.1. Drug Profile: Imfinzi
5.4.3.2. Drug Profile: Fasenra
5.4.3.3. Drug Profile: Anifrolumab
5.4.3.4. Drug Profile: Nirsevimab
5.4.3 Recent Developments and Future Outlook
5.5. Genentech
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Drug Portfolio
5.5.3.1. Drug Profile: Gazyva
5.5.3.2. Drug Profile: Tecentriq
5.5.3.3. Drug Profile: Ocrevus
5.5.4 Recent Developments and Future Outlook
5.6. MacroGenics
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Drug Portfolio
5.6.3.1. Drug Profile: Margenza
5.6.3.2. Drug Profile: Enoblituzumab
5.6.4. Recent Developments and Future Outlook
5.7. Kyowa Kirin
5.7.1. Company Overview
5.7.2. Financial Portfolio
5.7.3. Drug Portfolio
5.7.3.1. Drug Profile: POTELIGEO
5.7.4. Recent Developments and Future Outlook

6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models
6.3. Fc Protein Engineered and Glycoengineered Antibodies: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year of Partnership and Type of Partner
6.3.4. Analysis by Type of Partnership and Type of Partner
6.3.5. Most Active Players: Analysis by Number of Partnerships
6.3.6. Analysis by Therapeutic Area
6.3.7. Analysis by Type of Fc Engineering
6.3.8. Analysis by Type of Partnership, Therapeutic Area and Type of Fc Engineering
6.3.9. Regional Analysis
6.3.10. International and Intracontinental Agreements

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Fc Protein Engineered and Glycoengineered Antibodies: Clinical Trials
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Registration Year and Trial Status
7.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
7.3.4. Analysis by Trial Phase
7.3.5. Analysis by Trial Phase and Enrolled Patient Population
7.3.6. Analysis by Study Design
7.3.7. Analysis by Type of Sponsor / Collaborator
7.3.8. Most Active Industry Players: Analysis by Number of Registered Trials
7.3.9. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7.3.10. Analysis by Trial Focus
7.3.11. Analysis by Type of Drug Molecule
7.3.12. Analysis by Key Indications
7.3.13. Analysis by Therapeutic Area
7.3.14. Geographical Analysis by Number of Clinical Trials
7.3.15. Geographical Analysis by Number of Clinical Trials and Trial Status
7.3.16. Geographical Analysis by Enrolled Patient Population
7.3.17. Geographical Analysis by Enrolled Patient Population and Trial Status

8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Fc Protein Engineered and Glycoengineered Antibodies: Academic Grants Analysis
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Funding Institute Center
8.3.5. Analysis by Support Period
8.3.6. Analysis by Funding Institute Center and Support Period
8.3.7. Analysis by Type of Grant Application
8.3.8. Analysis by Purpose of Grant Award
8.3.9. Analysis by Activity Code
8.3.10. Word Cloud Analysis: Emerging Focus Areas
8.3.11. Analysis by Study Section Involved
8.3.12. Popular NIH Departments: Analysis by Number of Grants
8.3.13. Prominent Program Officers: Analysis by Number of Grants
8.3.14. Analysis by Type of Recipient Organization
8.3.15. Popular Recipient Organizations: Analysis by Number of Grants
8.3.16. Regional Distribution of Recipient Organizations

9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Fc Protein Engineered and Glycoengineered Antibodies: Patent Analysis
9.3.1. Analysis by Publication Year
9.3.2. Analysis by Issuing Authority / Patent Offices Involved
9.3.3. Analysis by CPC Symbols
9.3.4. Word Cloud: Emerging Focus Areas
9.3.5. Analysis by Type of Organization
9.3.6. Leading Players: Analysis by Number of Patents
9.3.7. Analysis by Patent Valuation
9.3.8. Leading Patents by Number of Citations

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Fc Protein and Glycoengineered Antibodies Market, 2021-2035
10.3.1. Fc Protein Engineered and Glycoengineered Antibodies Market, 2021-2035: Distribution by Type of Fc Engineering
10.3.1.1. Fc Protein Engineered and Glycoengineered Antibodies Market for Fc Protein Engineered Antibodies, 2021-2035
10.3.1.2. Fc Protein Engineered and Glycoengineered Antibodies Market for Fc Glycoengineered Antibodies, 2021-2035
10.3.2. Fc Protein Engineered and Glycoengineered Antibodies Market, 2021-2035: Distribution by Type of Therapy
10.3.2.1. Fc Protein Engineered and Glycoengineered Antibodies Market for Monotherapy, 2021-2035
10.3.2.2. Fc Protein Engineered and Glycoengineered Antibodies Market for Combination therapy, 2021-2035
10.3.3. Fc Protein Engineered and Glycoengineered Antibodies Market, 2021-2035: Distribution by Therapeutic Area
10.3.3.1. Fc Protein Engineered and Glycoengineered Antibodies Market for Oncological Disorders, 2021-2035
10.3.3.2. Fc Protein Engineered and Glycoengineered Antibodies Market for Rare Disorders, 2021-2035
10.3.3.3. Fc Protein Engineered and Glycoengineered Antibodies Market for Dermatological Disorders, 2021-2035
10.3.3.4. Fc Protein Engineered and Glycoengineered Antibodies Market for Autoimmune Disorders, 2021-2035
10.3.3.5. Fc Protein Engineered and Glycoengineered Antibodies Market for Infectious Diseases, 2021-2035
10.3.3.6. Fc Protein Engineered and Glycoengineered Antibodies Market for Gastrointestinal Disorders, 2021-2035
10.3.3.7. Fc Protein Engineered and Glycoengineered Antibodies Market for Neurological Disorders, 2021-2035
10.3.3.8. Fc Protein Engineered and Glycoengineered Antibodies Market for Pulmonary Disorders, 2021-2035
10.3.4. Fc Protein Engineered and Glycoengineered Antibodies Market, 2021-2035: Distribution by Route of Administration
10.3.4.1. Fc Protein Engineered and Glycoengineered Antibodies Market for Intravenous Route, 2021-2035
10.3.4.2. Fc Protein Engineered and Glycoengineered Antibodies Market for Subcutaneous Route, 2021-2035
10.3.4.3. Fc Protein Engineered and Glycoengineered Antibodies Market for Other Routes of Administration, 2021-2035
10.3.5. Fc Protein Engineered and Glycoengineered Antibodies Market, 2021-2035: Distribution by Geography
10.3.5.1. Fc Protein Engineered and Glycoengineered Antibodies Market in North America, 2021-2035
10.3.5.2. Fc Protein Engineered and Glycoengineered Antibodies Market in Europe, 2021-2035
10.3.5.3. Fc Protein Engineered and Glycoengineered Antibodies Market in North America, 2021-2035
10.3.5.4. Fc Protein Engineered and Glycoengineered Antibodies Market in Asia-Pacific, 2021-2035
10.3.6. Global Fc Protein and Glycoengineered Antibodies Market (For Clinical Late-Stage Products), 2021-2035
10.3.7. Global Fc Protein and Glycoengineered Antibodies Market (For Commercialized Products), 2021-2035

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS